MedTrace Logo

A Study of Distal Jejunal-release Dextrose in Obese Participants

NCT05385978 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-10-16

No results posted yet for this study

Summary

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in obese participants.

Conditions

Interventions

DRUG

APHD-012

Distal jejunal-release dextrose beads (Aphaia technology, AT)

DRUG

APHD-012P

Distal jejunal-release placebo beads

Sponsors & Collaborators

  • Aphaia Pharma US LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2024-11-11
Completion
2024-11-11
FDA Drug
Yes

Countries

  • Georgia
  • Germany
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385978 on ClinicalTrials.gov